Indian government has implemented a comprehensive policy framework to accelerate sector-wise growth, building on past ...

Key TakeawaysThe global vaccines market reached USD 87.57 billion in 2024 and is projected to grow to USD 206.78 billion by ...

US biotech fund BVF Parners has sold its stake in drug developer Syntara, thus exiting all of its ASX life sciences exposures ...

That challenge, of finding or building good, usable data sets, is also one of the biggest differentiators in an increasingly ...

Despite a strong cash position and no debt, my NPV model shows NUVB is fairly valued or overvalued at $1.73. Click here to ...

Merck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative modelling technology to speed up the discovery and design of promising new compounds.

Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.

Merck, a leading science and technology company ... More mature data for PROCEADE-CRC-01 and details on the design for the PROCEADE-PanTumor study investigating precemtabart tocentecan in patients ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

Fintel reports that on June 16, 2025, Piper Sandler upgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Neutral ...